Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy of tocilizumab versus prednisone in DMARD-insufficient response rheumatoid arthritis
2017-003037-28Phase 4Completed
- Sponsor
- University Medical Center Utrecht
- Start
- Jul 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised trial of tocilizumab in rheumatoid arthritis (RA) (2 arms), sponsored by University Medical Center Utrecht. Primary endpoint: Primary: Change in CDAI from baseline to 6, 9, and 12 months. Started Jul 2019; status: completed.
02
Drugs
tocilizumab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2017-003037-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-003037-28.